EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Clinical trial NCT07339527 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07339527
Sponsor: Sun Yat-sen University
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Mature T-cell and NK-cell Lymphoma

Start date: 2026-01-01
Primary completion: 2028-01-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.